Message From Chairman

I'm pleased and honored to be in touch with the staff and clients of Misr pharmaceuticals company , I'm also pleased to summarize the most              important results as follows                                                                    

• Revenues from operations reached LE 527 million during the fiscal year 2023/2024 compared to LE 478.8 million recorded in the previous fiscal year, with an increase of LE 48.2 million and by rate of 10 %

• The value of the net sales (local and export) amounted to LE 522.5 million during the fiscal year 2023/2024 compared to LE 406 million recorded in the previous fiscal year, with an increase of LE 54.4 million and by rate of 11%

• The value of exports amounted to LE 47 million during the fiscal year 2023/2024 compared to LE 73.3 million recorded in the previous fiscal year

• The value of production at the selling price amounted to LE 488 million during the fiscal year 2023/2024 compared to LE 490 million recorded in the previous fiscal year

• The value of net distributable  profit amounted LE 48.3 million during the fiscal year 2023/2024 (represents 9 % of   Revenues)                           

** It is worth nothing that the company was able to achieve these results despite the cessation of the production departments in the beta and non- beta factories since February 2024 , and the movement of sales, inventory and liquidity were affected for a period of 5 consecutive months ,which are exceptional  and unprecedented circumstances, for development and modernization work to comply  with the GMP and license of the Medicines Authority                                                                 

**We would also like to point out that  the company has completed development   and modernization work at a rate of more than 95%            

Dr / Khaled Atef El-Monery